FDA Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of MM in Patients Who Have Received One or More Prior Therapies

Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.
Source: International Myeloma Foundation - Category: Hematology Source Type: news